• Fresenius unit Fresenius Kabi struck a deal with Waltz Health to sell three biosimilars directly to employers, payers, PBMs.
• Access will run through the Waltz Connect platform under a transparent, per-unit contract pricing model that avoids traditional rebate structures.
• Prescriptions will be dispensed via an EVERSANA-operated specialty pharmacy, shipped to patients’ homes, bypassing wholesalers and rebate-driven PBM channels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via PR Newswire (Ref. ID: CG58373) on September 29, 2026, and is solely responsible for the information contained therein.